REGENXBIO Inc. Stock-Based Compensation
REGENXBIO Inc. (RGNX) reported Stock-Based Compensation of $17.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- REGENXBIO Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $9.05M, a 4.62% increase year-over-year.
- REGENXBIO Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $8.62M, a 0.94% increase year-over-year.
- REGENXBIO Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $8.38M, a 12.23% decline year-over-year.
- REGENXBIO Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $9.00M, a 8.96% decline year-over-year.
- REGENXBIO Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $34.56M, a 10.14% decline from fiscal 2024.
- REGENXBIO Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $38.46M, a 4.48% decline from fiscal 2023.
- REGENXBIO Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $40.27M, a 1.28% decline from fiscal 2022.
- REGENXBIO Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $40.79M, a 5.10% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $17.67M 10-Q · filed 2026-08-06 | $26.05M derived: sum of 3 quarters · filed 2026-08-06 | $35.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $8.62M 10-Q · filed 2026-05-14 | $16.99M derived: sum of 2 quarters · filed 2026-05-14 | $25.99M derived: sum of 3 quarters · filed 2026-05-14 | $34.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $8.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $17.37M derived: sum of 2 quarters · filed 2026-03-05 | $26.03M derived: sum of 3 quarters · filed 2026-08-06 | $34.56M 10-K · filed 2026-03-05 |
| 2025-09-30 | $9.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $17.65M derived: sum of 2 quarters · filed 2026-08-06 | $26.19M 10-Q · filed 2025-11-06 | $35.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $8.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $17.19M 10-Q · filed 2026-08-06 | $26.73M derived: sum of 3 quarters · filed 2026-08-06 | $36.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $8.54M 10-Q · filed 2026-05-14 | $18.08M derived: sum of 2 quarters · filed 2026-05-14 | $27.96M derived: sum of 3 quarters · filed 2026-05-14 | $37.40M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $9.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $19.43M derived: sum of 2 quarters · filed 2026-03-05 | $28.86M derived: sum of 3 quarters · filed 2026-03-05 | $38.46M 10-K · filed 2026-03-05 |
| 2024-09-30 | $9.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $19.32M derived: sum of 2 quarters · filed 2025-11-06 | $28.92M 10-Q · filed 2025-11-06 | $37.26M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $9.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $19.04M 10-Q · filed 2025-08-07 | $27.38M derived: sum of 3 quarters · filed 2025-08-07 | $37.59M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $9.60M 10-Q · filed 2025-05-12 | $17.94M derived: sum of 2 quarters · filed 2025-05-12 | $28.16M derived: sum of 3 quarters · filed 2025-05-12 | $38.66M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $8.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $18.56M derived: sum of 2 quarters · filed 2025-03-13 | $29.06M derived: sum of 3 quarters · filed 2025-03-13 | $40.27M 10-K · filed 2025-03-13 |
| 2023-09-30 | $10.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $20.72M derived: sum of 2 quarters · filed 2024-11-06 | $31.93M 10-Q · filed 2024-11-06 | $41.34M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $10.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $21.71M 10-Q · filed 2024-08-01 | $31.12M derived: sum of 3 quarters · filed 2025-03-13 | $41.36M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $11.21M 10-Q · filed 2024-05-08 | $20.61M derived: sum of 2 quarters · filed 2025-03-13 | $30.86M derived: sum of 3 quarters · filed 2025-03-13 | $41.19M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $9.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $19.65M derived: sum of 2 quarters · filed 2025-03-13 | $29.99M derived: sum of 3 quarters · filed 2025-03-13 | $40.79M 10-K · filed 2025-03-13 |
| 2022-09-30 | $10.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $20.58M derived: sum of 2 quarters · filed 2023-11-08 | $31.38M 10-Q · filed 2023-11-08 | $40.54M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $10.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $21.14M 10-Q · filed 2023-08-02 | $30.30M derived: sum of 3 quarters · filed 2024-02-27 | $40.03M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $10.80M 10-Q · filed 2023-05-03 | $19.96M derived: sum of 2 quarters · filed 2024-02-27 | $29.70M derived: sum of 3 quarters · filed 2024-02-27 | $39.69M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $9.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $18.90M derived: sum of 2 quarters · filed 2024-02-27 | $28.89M derived: sum of 3 quarters · filed 2024-02-27 | $38.81M 10-K · filed 2024-02-27 |
| 2021-09-30 | $9.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $19.73M derived: sum of 2 quarters · filed 2022-11-03 | $29.65M 10-Q · filed 2022-11-03 | $37.23M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $9.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $19.91M 10-Q · filed 2022-08-03 | $27.49M derived: sum of 3 quarters · filed 2023-02-28 | $35.53M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $9.92M 10-Q · filed 2022-05-04 | $17.50M derived: sum of 2 quarters · filed 2023-02-28 | $25.54M derived: sum of 3 quarters · filed 2023-02-28 | $33.85M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $7.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $15.62M derived: sum of 2 quarters · filed 2023-02-28 | $23.93M derived: sum of 3 quarters · filed 2023-02-28 | $31.95M 10-K · filed 2023-02-28 |
| 2020-09-30 | $8.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $16.35M derived: sum of 2 quarters · filed 2021-11-02 | $24.37M 10-Q · filed 2021-11-02 | $31.24M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $8.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $16.33M 10-Q · filed 2021-08-09 | $23.21M derived: sum of 3 quarters · filed 2022-03-01 | $30.37M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $8.02M 10-Q · filed 2021-05-05 | $14.89M derived: sum of 2 quarters · filed 2022-03-01 | $22.05M derived: sum of 3 quarters · filed 2022-03-01 | $29.15M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $6.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $14.04M derived: sum of 2 quarters · filed 2022-03-01 | $21.14M derived: sum of 3 quarters · filed 2022-03-01 | $26.85M 10-K · filed 2022-03-01 |
| 2019-09-30 | $7.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $14.26M derived: sum of 2 quarters · filed 2020-11-04 | $19.98M 10-Q · filed 2020-11-04 | $24.86M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $7.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $12.82M 10-Q · filed 2020-08-06 | $17.70M derived: sum of 3 quarters · filed 2021-03-01 | $22.19M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $5.72M 10-Q · filed 2020-05-07 | $10.60M derived: sum of 2 quarters · filed 2021-03-01 | $15.09M derived: sum of 3 quarters · filed 2021-03-01 | $19.07M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $4.89M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $9.37M derived: sum of 2 quarters · filed 2021-03-01 | $13.35M derived: sum of 3 quarters · filed 2021-03-01 | $16.64M 10-K · filed 2021-03-01 |
| 2018-09-30 | $4.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $8.46M derived: sum of 2 quarters · filed 2019-11-05 | $11.76M 10-Q · filed 2019-11-05 | $14.55M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $3.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $7.27M 10-Q · filed 2019-08-07 | $10.07M derived: sum of 3 quarters · filed 2020-02-26 | $12.80M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $3.29M 10-Q · filed 2019-05-07 | $6.09M derived: sum of 2 quarters · filed 2020-02-26 | $8.82M derived: sum of 3 quarters · filed 2020-02-26 | $11.30M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $5.53M derived: sum of 2 quarters · filed 2020-02-26 | $8.01M derived: sum of 3 quarters · filed 2020-02-26 | $10.61M 10-K · filed 2020-02-26 |
| 2017-09-30 | $2.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $5.22M derived: sum of 2 quarters · filed 2018-11-07 | $7.81M 10-Q · filed 2018-11-07 | $9.81M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $5.07M 10-Q · filed 2018-08-08 | $7.07M derived: sum of 3 quarters · filed 2019-02-27 | $8.90M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $2.59M 10-Q · filed 2018-05-08 | $4.59M derived: sum of 2 quarters · filed 2019-02-27 | $6.42M derived: sum of 3 quarters · filed 2019-02-27 | $8.08M derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $3.83M derived: sum of 2 quarters · filed 2019-02-27 | $5.49M derived: sum of 3 quarters · filed 2019-02-27 | $7.03M 10-K · filed 2019-02-27 |
| 2016-09-30 | $1.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $3.48M derived: sum of 2 quarters · filed 2017-11-08 | $5.03M 10-Q · filed 2017-11-08 | $5.89M derived: sum of 4 quarters · filed 2018-03-06 |
| 2016-06-30 | $1.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $3.20M 10-Q · filed 2017-08-08 | $4.06M derived: sum of 3 quarters · filed 2018-03-06 | $5.41M derived: sum of 4 quarters · filed 2018-03-06 |
| 2016-03-31 | $1.55M 10-Q · filed 2017-05-09 | $2.41M derived: sum of 2 quarters · filed 2018-03-06 | $3.76M derived: sum of 3 quarters · filed 2018-03-06 | $4.39M derived: sum of 4 quarters · filed 2018-03-06 |
| 2015-12-31 | $862.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $2.21M derived: sum of 2 quarters · filed 2018-03-06 | $2.85M derived: sum of 3 quarters · filed 2018-03-06 | $2.92M 10-K · filed 2018-03-06 |
| 2015-09-30 | $1.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $1.98M derived: sum of 2 quarters · filed 2016-11-09 | $2.06M 10-Q · filed 2016-11-09 | $2.16M derived: sum of 4 quarters · filed 2017-03-07 |
| 2015-06-30 | $635.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $711.00K 10-Q · filed 2016-08-09 | $810.00K derived: sum of 3 quarters · filed 2017-03-07 | |
| 2015-03-31 | $76.00K 10-Q · filed 2016-05-05 | $175.00K derived: sum of 2 quarters · filed 2017-03-07 | ||
| 2014-12-31 | $99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | $319.00K 10-K · filed 2017-03-07 | ||
| 2014-09-30 | $220.00K 10-Q · filed 2015-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |